ClinicalTrials.gg
RecruitingNCT06109064Updated Oct 31, 2023

Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS

A Phase 2 interventional study of Unrelated Umbilical Cord Blood and Venetoclax in Myelodysplastic Syndromes, sponsored by Anhui Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 14 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-31.

Sponsored by Anhui Provincial Hospital · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
14 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 117 studies in Myelodysplastic Syndromes with a site in China — 55 open to participants now, 62 under way, 7 of them phase 3. Myelodysplastic Syndromes · China.

Planned enrollment
97th of 102
14 · median 76
Started
2023
with 15 others
Phase 2
31 of 117
18 open now
Primary completion
2024-02
later than 1 of 61 live
Registered
83rd of 117
by date

Among the 117 studies in Myelodysplastic Syndromes with a site in China, this one is the 97th largest by planned enrollment of the 102 interventional ones that give a count, is one of 16 that started in 2023, is one of 31 in phase 2, reaches primary completion later than 1 of the 61 other live ones, and was the 83rd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

55 of the 117 studies in Myelodysplastic Syndromes with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 14 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Myelodysplastic Syndromes with a site in China, or all of them as a file.
02

Study summary

This study aimed to evaluate the safety and efficacy of unrelated umbilical cord blood microtransplantation in the treatment of above-mentioned MDS patients by observing the factors related to the efficacy and adverse reactions.

03

Conditions studied

  • Myelodysplastic Syndromes
04

Who can participate

Ages eligible
14 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with MDS with WHO criteria through bone marrow morphology, histochemistry, immunophenotyping, pathological testing, etc. Patients can be newly diagnosed, recurrent or unresponsive, with International prognostic scoring system (IPSS-R) score> 3.5
  2. Patients aged 14-80, gender and race are not limited;
  3. score ≥ 60%, (ECOG) performance status ≤ 2;
  4. Expected survival time ≥ 3 months;
  5. The examination results meet the following requirements:

    and AST ≤ 3 × value (ULN); Total ≤ 3 × ULN; Creatinine ≤ 2 × ULN or rate ≥ 40mL/min; The (LVEF) measured by echocardiography or multigated acquisition (MUGA) scanning is within the normal range (>50%);

  6. The recipient and selected donor should be 0-3/10 HLA-matched with same blood type;
  7. Patients who voluntarily participate in this clinical study and have signed an .

Exclusion criteria

Exclusion Criteria:

  1. Patients who have suffered from malignant tumors;
  2. Patients have suffered from hematopoietic failure after chemotherapy, and have undergone ineffective blood transfusion with unknown cause;
  3. Patients who have undergone Class II or above surgery within 4 weeks prior to enrollment;
  4. Suffering from life-threatening diseases other than MDS;
  5. Allergic to the drugs in the research;
  6. Patient with severe cardiac insufficiency, including uncontrolled or symptomatic arrhythmia, congestive heart failure, myocardial infarction within 6 months, or any grade 3 (moderate) or grade 4 (severe) heart disease;
  7. Patients with test positive for , or ;
  8. Stroke or intracranial hemorrhage occurred within 6 months prior to enrollment;
  9. Warfarin or vitamin K antagonists (such as phenprocoumarin) is necessary for anticoagulation;
  10. Patients with mental illnesses or cognitive impairments;
  11. Patients have participated within the month prior to enrollment or patients are currently participating in other clinical trials;
  12. There are other conditions that the investigators consider inappropriate for inclusion.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    chemotherapy+Unrelated Umbilical Cord Blood microtransplantation

    Intermittent infusion of HLA mismatched or incompletely matched granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells (G-PBSC) during routine chemotherapy without the use of immunosuppressants, abbreviated as "microtransplantation"

    Biological: Unrelated Umbilical Cord Blood · Drug: Venetoclax · Drug: Decetabine · Drug: Azacitidine

Interventions

  • BiologicalUnrelated Umbilical Cord Blood

    The requirements of unrelated umbilical cord blood: recipient-donor HLA match is 0-3/10, same blood type.

  • Patients will be treated with Venetoclax (100 mg on day 1, 200 mg on day 2 and 400 mg on days 3 to 21)

  • Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)

  • Patients will be treated with Decetabine (20mg/m\^2/d on days 1 to 5) or Azacitidine (75mg/m\^2/d on days 1 to 7)

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rate

    CR rate is defined as the percentage of patients who met the following conditions: Myelogram: naïve cells less than 5% (at least 200 nucleated cells); Hemogram: absolute neutrophil count \> 1.0×10\^9/L, platelet count \> 100×10\^9/L; Clinical diagnosis: no symptoms and signs caused by leukemia infiltration, and patients do not rely on blood transfusion.

    Time frame: 28±7 days

  2. Hematopoietic recovery time

    The time of absolute neutrophil count\>0.5×10\^9/L and platelet count \>30×10\^9/L for 3 consecutive days.

    Time frame: 28±7 days

Secondary outcomes

  1. Time to Progression(TTP)

    Time from enrollment to objective progression of disease

    Time frame: 1 year

  2. Disease Free Survival(DFS)

    From CR to recurrence or death or to the date of last follow-up

    Time frame: 1 year

  3. Overall Survival(OS)

    From the beginning of treatment to death or to the date of last follow-up

    Time frame: 1 year

  4. Early mortality rate

    Death within the first 3 months of induction therapy

    Time frame: 3 months

Other outcomes

  1. Changes in lymphocyte subsets (NK cells, T cells) before and after treatment

    The concentration of lymphocyte subsets in peripheral blood can be detected by flow cytometry

    Time frame: At the time of enrollment and at 1 month

  2. Correlation between human leukocyte antigen (HLA) matching and the concentration of lymphocyte subsets

    HLA typing and matching can be assessed by sequence based genotyping (PCR-SBT), and the concentration of lymphocyte subsets in peripheral blood can be detected by flow cytometry

    Time frame: HLA typing and matching will be assessed at the time of enrollment, and the concentration of lymphocyte subsets in peripheral blood will be detected at the time of enrollment and at 1 month

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2023; primary completion for Feb 2024, 3 months later.

Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 3 months is below that.

Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 31, 2023
StartEst.
Oct 27, 2023
Primary completionEst.
Feb 1, 2024
CompletionEst.
Feb 1, 2026
Last update
Oct 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06109064
Responsible party
Xiaoyu Zhu (Principal Investigator, Anhui Provincial Hospital) — Principal investigator
First posted
Oct 31, 2023
Start date
Oct 27, 2023 (estimated)
Primary completion
Feb 1, 2024 (estimated)
Completion
Feb 1, 2026 (estimated)
Last update
Oct 31, 2023

Study contacts

Xiaoyu Zhu, MD
Contact
xiaoyuz@ustc.edu.cn
15255456091
Xiaoyu Zhu, MD
principal investigator · The First Affiliated Hospital of University of Science and Technology of China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion